These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38819314)

  • 1. Rejoinder to the discussion on "Bayesian meta-analysis of penetrance for cancer risk".
    Ruberu TLM; Braun D; Parmigiani G; Biswas S
    Biometrics; 2024 Mar; 80(2):. PubMed ID: 38819314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian meta-analysis of penetrance for cancer risk.
    Ruberu TLM; Braun D; Parmigiani G; Biswas S
    Biometrics; 2024 Mar; 80(2):. PubMed ID: 38819308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discussion on "Bayesian meta-analysis of penetrance for cancer risk" by Thanthirige Lakshika M. Ruberu, Danielle Braun, Giovanni Parmigiani, and Swati Biswas.
    Ursino M; Zohar S
    Biometrics; 2024 Mar; 80(2):. PubMed ID: 38819315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discussion on "Bayesian meta-analysis of penetrance for cancer risk" by Thanthirige Lakshika M. Ruberu, Danielle Braun, Giovanni Parmigiani, and Swati Biswas.
    Baio G
    Biometrics; 2024 Mar; 80(2):. PubMed ID: 38819312
    [No Abstract]   [Full Text] [Related]  

  • 5. Discussion on "Bayesian meta-analysis of penetrance for cancer risk" by Thanthirige Lakshika M. Ruberu, Danielle Braun, Giovanni Parmigiani, and Swati Biswas.
    Gustafson P
    Biometrics; 2024 Mar; 80(2):. PubMed ID: 38819311
    [No Abstract]   [Full Text] [Related]  

  • 6. Discussion on "Bayesian meta-analysis of penetrance for cancer risk" by Thanthirige Lakshika M. Ruberu, Danielle Braun, Giovanni Parmigiani, and Swati Biswas.
    Banerjee S
    Biometrics; 2024 Mar; 80(2):. PubMed ID: 38819310
    [No Abstract]   [Full Text] [Related]  

  • 7. Discussion on "Bayesian meta-analysis of penetrance for cancer risk" by Thanthirige Lakshika M. Ruberu, Danielle Braun, Giovanni Parmigiani, and Swati Biswas.
    Müller P; Flores B
    Biometrics; 2024 Mar; 80(2):. PubMed ID: 38819313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rejoinder on "ascertainment adjustment in complex diseases".
    Glidden DV
    Genet Epidemiol; 2002 Oct; 23(3):219-20. PubMed ID: 12384974
    [No Abstract]   [Full Text] [Related]  

  • 9. Penetrance of male breast cancer susceptibility genes: a systematic review.
    Chamseddine RS; Wang C; Yin K; Wang J; Singh P; Zhou J; Robson ME; Braun D; Hughes KS
    Breast Cancer Res Treat; 2022 Jan; 191(1):31-38. PubMed ID: 34642874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Penetrance of ATM Gene Mutations in Breast Cancer: A Meta-Analysis of Different Measures of Risk.
    Marabelli M; Cheng SC; Parmigiani G
    Genet Epidemiol; 2016 Jul; 40(5):425-31. PubMed ID: 27112364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating penetrance from multiple case families with predisposing mutations: extension of the 'genotype-restricted likelihood' (GRL) method.
    Bonaïti B; Bonadona V; Perdry H; Andrieu N; Bonaïti-Pellié C
    Eur J Hum Genet; 2011 Feb; 19(2):173-9. PubMed ID: 20924409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating genetic variants associated with breast cancer risk in high and moderate-penetrance genes in Asians.
    Han MR; Zheng W; Cai Q; Gao YT; Zheng Y; Bolla MK; Michailidou K; Dennis J; Wang Q; Dunning AM; Brennan P; Chen ST; Choi JY; Hartman M; Ito H; Lophatananon A; Matsuo K; Miao H; Muir K; Sangrajrang S; Shen CY; Teo SH; Tseng CC; Wu AH; Yip CH; Kang D; Xiang YB; Easton DF; Shu XO; Long J
    Carcinogenesis; 2017 May; 38(5):511-518. PubMed ID: 28419251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating cumulative risks for breast cancer for carriers of variants in uncommon genes.
    Lindor NM; Hopper J; Dowty J
    Fam Cancer; 2016 Jul; 15(3):367-70. PubMed ID: 26960971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
    Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
    Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-Analysis of Breast Cancer Risk for Individuals with PALB2 Pathogenic Variants.
    Ruberu TLM; Braun D; Parmigiani G; Biswas S
    medRxiv; 2024 Mar; ():. PubMed ID: 37398422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred.
    Vogl FD; Badzioch MD; Steele L; Neuhausen SL; Goldgar DE
    Fam Cancer; 2007; 6(1):63-71. PubMed ID: 17051349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comment on "Ascertainment adjustment in complex diseases".
    Epstein MP
    Genet Epidemiol; 2002 Oct; 23(3):209-13. PubMed ID: 12384972
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetic risk of breast cancer.
    Nasir A; Shackelford RE; Anwar F; Yeatman TJ
    Minerva Endocrinol; 2009 Dec; 34(4):295-309. PubMed ID: 20046159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: a meta-analytic approach.
    Fu R; Harris EL; Helfand M; Nelson HD
    Stat Med; 2007 Apr; 26(8):1775-87. PubMed ID: 17243094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.